An Open-label Study to Investigate ECUR-506 in Male Babies Less Than 9 Months of Age With Neonatal Onset OTC Deficiency (OTC-HOPE)

Ornithine Transcarbamylase Deficiency Clinical Trial

Official title: A Phase I/II First-in-Human, Open-Label, Dose-Escalation Study to Evaluate the Safety and Efficacy of a Single Intravenous (IV) Administration of ECUR-506 in Males Less Than 9 Months of Age With Genetically Confirmed Neonatal Onset Ornithine Transcarbamylase (OTC) Deficiency

Status Recruiting

Clinical Trial Summary

Ornithine Transcarbamylase (OTC) deficiency, the most common urea cycle disorder, is an inherited metabolic disorder caused by a genetic defect in a liver enzyme responsible for detoxification of ammonia. Individuals with OTC deficiency can build-up excess levels of ammonia in their blood, potentially resulting in devastating consequences, including cumulative and irreversible neurological damage, coma and death. The severe form of the condition emerges shortly after birth and is more common in boys than girls. This is a Phase 1/2, open-label, multicenter, safety and dose finding study of ECUR-506 in male babies with neonatal onset OTC deficiency. The primary objective of this study is to evaluate the safety and tolerability of up to two dose levels of ECUR-506 following intravenous (IV) administration of a single dose.

Clinical Trial Description

The study drug, ECUR-506, is an investigational gene editing therapy. Gene editing is a way to repair, replace, or introduce new copies of genes that don't work. The study drug contains a working copy of the OTC gene that will be delivered by an IV infusion. It also contains a gene to encode the editing enzyme which is the part of the study drug that can cut DNA so that the OTC gene can be inserted. The study drug was designed to introduce a working copy of the OTC gene and a gene to encode the editing enzyme. A gene cannot enter cells by itself, it needs a delivery mechanism to move the gene into the cells. In this study, the carrier is called adeno-associated virus (AAVs) that is able to enter cells and deliver these genes. This is a commonly found virus that has been changed to make it essentially harmless. ;

Related Conditions & MeSH terms

• Deficiency Diseases
• Ornithine Transcarbamylase Deficiency
• Ornithine Transcarbamylase Deficiency Disease
• Urea Cycle Disorders, Inborn

• NCT number: NCT06255782
• Study type: Interventional
• Source: iECURE, Inc.
• Contact: George Diaz, M.D., Ph.D.
• Phone: 1-877-694-3558
• Email: medinfo@iecure.com
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: April 2024
• Completion date: September 2026